Neuromyelitis optica IgG and natural killer cells produce NMO lesions in mice without myelin loss.
about
Aquaporin 4 and neuromyelitis opticaThe Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future PerspectivesPhysiological roles of aquaporin-4 in brainInebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical StudiesImmunology of neuromyelitis optica during pregnancyTreatment of neuromyelitis optica: state-of-the-art and emerging therapiesOptic neuritis in neuromyelitis optica.Neuromyelitis optica: clinical features, immunopathogenesis and treatment.CNS Aquaporin-4-specific B cells connect with multiple B-cell compartments in neuromyelitis optica spectrum disorder.Differential contribution of immune effector mechanisms to cortical demyelination in multiple sclerosis.Biology of AQP4 and anti-AQP4 antibody: therapeutic implications for NMO.The treatment of neuromyelitis optica.The cerebrospinal fluid immunoglobulin transcriptome and proteome in neuromyelitis optica reveals central nervous system-specific B cell populations.Early loss of oligodendrocytes in human and experimental neuromyelitis optica lesions.Neuromyelitis optica pathology in rats following intraperitoneal injection of NMO-IgG and intracerebral needle injury.Influenza-associated MOG antibody-positive longitudinally extensive transverse myelitis: a case report.Human immunoglobulin G reduces the pathogenicity of aquaporin-4 autoantibodies in neuromyelitis opticaThe intrinsic pathogenic role of autoantibodies to aquaporin 4 mediating spinal cord disease in a rat passive-transfer modelAquaporin-4 antibody isoform binding specificities do not explain clinical variations in NMOHydroxycholesterol Levels in the Serum and Cerebrospinal Fluid of Patients with Neuromyelitis Optica Revealed by LC-Ag+CIS/MS/MS and LC-ESI/MS/MS with Picolinic Derivatization: Increased Levels and Association with Disability during Acute Attack.Enzymatic deglycosylation converts pathogenic neuromyelitis optica anti-aquaporin-4 immunoglobulin G into therapeutic antibody.Paucity of natural killer and cytotoxic T cells in human neuromyelitis optica lesions.Clobetasol promotes remyelination in a mouse model of neuromyelitis opticaNeuromyelitis optica: aquaporin-4 based pathogenesis mechanisms and new therapies.Characterization of the binding pattern of human aquaporin-4 autoantibodies in patients with neuromyelitis optica spectrum disordersComplement-independent retinal pathology produced by intravitreal injection of neuromyelitis optica immunoglobulin G.Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD.Involvement of antibody-dependent cell-mediated cytotoxicity in inflammatory demyelination in a mouse model of neuromyelitis optica.C1q-targeted monoclonal antibody prevents complement-dependent cytotoxicity and neuropathology in in vitro and mouse models of neuromyelitis optica.Unique neuromyelitis optica pathology produced in naïve rats by intracerebral administration of NMO-IgGB cells in MS and NMO: pathogenesis and therapy.Eosinophil pathogenicity mechanisms and therapeutics in neuromyelitis optica.Identification of a point mutation impairing the binding between aquaporin-4 and neuromyelitis optica autoantibodies.Neuromyelitis Optica: Deciphering a Complex Immune-Mediated Astrocytopathy.Complement-dependent and -independent aquaporin 4-antibody-mediated cytotoxicity in human astrocytes: Pathogenetic implications in neuromyelitis optica.The immunogenetics of neurological disease.Pattern Recognition of the Multiple Sclerosis Syndrome.Genome expression profiling predicts the molecular mechanism of peripheral myelination.Determining the Spatial Relationship of Membrane-Bound Aquaporin-4 Autoantibodies by STED Nanoscopy.Neuromyelitis optica spectrum disorders and pregnancy: Interactions and management.
P2860
Q24613666-1A521519-1B78-4397-87EB-CBE9C1E8BBEFQ26767391-B01DB672-B9E3-4FB6-A34E-39F4CDF30001Q26866009-8ECF31AB-4F10-4D6B-B0F9-F2A39729DE5EQ28067334-73D28A4B-D3F8-4984-891B-6A49E852712CQ28078470-8973BB5E-A2BC-4355-8152-570756B3D1BDQ28245749-4D16B4C0-0361-4188-848E-5C8543DB5802Q30610471-32FF5D5E-FB5A-498D-8544-EAF6D5C10014Q30785267-D634AB4C-BE83-45EF-A18D-1ECFBD50276BQ33753860-0A875882-1E65-4D8C-8505-6BCF1E4629F9Q33841113-ABFBE494-6001-4065-A0CC-835DAE66C597Q34377212-11A482EB-AEF9-4685-8D3E-A84BBC020EA4Q34399291-AFBB964F-E7E2-4DCF-9948-5E14C02FC936Q34459965-13E7B92C-B9C2-4BD8-9495-074C58AD068AQ34497097-FCC6F38C-B7D5-4A8A-9683-09C541907720Q34529121-12A338DA-820E-460A-A4BA-4D29E168C2BFQ34636918-C72AA0EF-343C-4DFA-9AD6-09E70EE9EE5DQ34919661-F557333A-7F18-4742-B662-07B26263AD48Q35242214-A0B8EEBC-844F-4021-ACE8-3FFF7753A9EBQ35764733-8E602D28-2DDE-44FE-9F42-45D009ECE3FFQ36220053-843E1E42-20A5-4428-8191-685D8400F6EEQ36596808-A16C7FEE-25F5-46D1-AF68-E2E25BF0F867Q36661685-D34688AF-FFB7-4C1E-9781-573285ABC1A4Q36836541-575AAC38-974A-4B71-9BFE-48929204ADD3Q36911907-AB99C4BA-D446-4C75-8EF2-82F3A1159575Q37059594-66367F3F-0ECF-4538-A925-FB89E2C9865AQ37353732-B3187108-D379-4246-A048-0619E19420F6Q37402026-F4812551-06E4-413E-ABF0-9CAD167C2C6BQ37472990-0D91FBB6-2779-490E-8810-BFA78D280310Q37615906-0836C483-392D-442D-B970-E632FAA005F0Q37638498-9B51DA1F-4244-436E-AEFF-FAD4BA2F4274Q38212081-B0DD947F-45C9-425B-81D2-43FE6A85C9BAQ40092095-1E4C0108-F7D3-44A6-9C17-290E7843D55BQ41818298-A61F244D-B1E6-4695-BDE2-B75A7AB7A3B0Q42844764-BD513B9A-71FA-4FA4-A3E1-A04F9396000DQ44945605-2C0C8D48-13EF-41BD-80E5-D85368740D74Q46094020-502D086A-EB4A-45FC-A07B-B8F8D74B2A93Q47096340-E9B4311F-C710-4827-9C53-E02813A9CF88Q47235583-20BDFF3C-E566-4EEE-BFDE-30E0AE1B7D82Q47870931-E1609C2D-120C-45E5-B14C-898495B071C6Q49873825-63208369-2BA6-41D6-B9A5-0EBA6974FB53
P2860
Neuromyelitis optica IgG and natural killer cells produce NMO lesions in mice without myelin loss.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Neuromyelitis optica IgG and n ...... s in mice without myelin loss.
@ast
Neuromyelitis optica IgG and n ...... s in mice without myelin loss.
@en
type
label
Neuromyelitis optica IgG and n ...... s in mice without myelin loss.
@ast
Neuromyelitis optica IgG and n ...... s in mice without myelin loss.
@en
prefLabel
Neuromyelitis optica IgG and n ...... s in mice without myelin loss.
@ast
Neuromyelitis optica IgG and n ...... s in mice without myelin loss.
@en
P2093
P2860
P1476
Neuromyelitis optica IgG and n ...... s in mice without myelin loss.
@en
P2093
A S Verkman
Jeffrey L Bennett
Julien Ratelade
Marios C Papadopoulos
Samira Saadoun
P2860
P2888
P304
P356
10.1007/S00401-012-0986-4
P577
2012-04-22T00:00:00Z